| Literature DB >> 20188552 |
Hwei-Ru Tsou1, Gloria MacEwan, Gary Birnberg, George Grosu, Matthew G Bursavich, Joel Bard, Natasja Brooijmans, Lourdes Toral-Barza, Irwin Hollander, Tarek S Mansour, Semiramis Ayral-Kaloustian, Ker Yu.
Abstract
We discovered 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Since phenolic OH groups pose metabolic liability, one of the two hydroxyl groups was selectively removed. The SAR data showed the structural features necessary for subnanomolar inhibitory activity against mTOR kinase as well as selectivity over PI3Kalpha. An X-ray co-crystal structure of one inhibitor with the mTOR-related PI3Kgamma revealed the key hydrogen bonding interactions. 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20188552 DOI: 10.1016/j.bmcl.2010.01.135
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823